Bharat Biotech launches oral cholera vaccine
Bharat Biotech International Ltd has launched Hillchol (BBV131), a novel single-strain oral cholera vaccine developed under license from Hilleman Laboratories.
Bharat Biotech International Ltd on Tuesday announced the launch of Hillchol, a novel single-strain oral cholera vaccine. A press release from the vaccine maker said Hillchol (BBV131) was developed by Bharat Biotech under license from Hilleman Laboratories (funded by Merck USA and Wellcome Trust) to combat Cholera.
Global demand for Oral Cholera Vaccines (OCVs) exceeds 100 million doses annually, making them crucial for cholera control. Globally, there is a shortage of OCVs as there is only one manufacturer. BBIL has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of Hillchol, it further said.
A multi-stage, clinical evolution process, culminating in a phase 3 study confirmed the vaccine safety, immunogenicity, and non-inferiority to existing OCVs, establishing its potential for white spirit, and public health use. The vaccine, a single dose capsule, is administered orally on days 0 and 14 and is suitable for individuals older than one year.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Senior Citizen Latest FD Rates: Know what major banks like SBI, PNB, Canara Bank, HDFC Bank, ICICI Bank are providing on fixed deposits
Gratuity Calculator: Rs 38,000 as last-drawn basic salary, 5 years and 5 months of service; what will be gratuity amount?
Top 5 Small Cap Mutual Funds with best SIP returns in 1 year: See how Rs 25,000 monthly investment has grown in each scheme
Top 7 SBI Mutual Funds With Best SIP Returns in 1 Year: Rs 25,000 monthly SIP investment in No.1 fund has jumped to Rs 3,58,404
03:09 PM IST